NEW YORK, NY--(Marketwire - Nov 13, 2012) - The Bedford Report has released new equity reports today. As a leading provider of free in depth reports and timely market updates, Bedford is an essential resource for hundreds of thousands of investors across the country.
Array Biopharma Inc. (NASDAQ: ARRY) shares of the biotech company have fallen sharply since announcing plans for a secondary stock offering. Shares of the company have dropped nearly 25 percent in the last week.
Find out more about Array Biopharma including full access to the free equity report at: www.BedfordReport.com/ARRY
Career Education Corp. (NASDAQ: CECO) shares of the for-profit educator have fallen over 20 percent in the past week. The company has failed to renew their $185 million credit agreement, which expired on October 31.
Find out more about Career Education including full access to the free equity report at: www.BedfordReport.com/CECO
Gilead Sciences, Inc. (NASDAQ: GILD) shares of the major biotechnology company hit a new 52-week high Monday after reporting positive data for their hepatitis C treatment.
Find out more about Gilead Sciences including full access to the free equity report at: www.BedfordReport.com/GILD
Nektar Therapeutics (NASDAQ: NKTR) shares declined 13.62 percent on nearly 10 times the average daily volume Monday. Analysts at Jefferies Group have downgraded the company from a buy rating to a hold.
Find out more about Nektar Therapeutics including full access to the free equity report at: www.BedfordReport.com/NKTR
Disclaimer: Equity News Circuit is not a registered investment advisor, and nothing in this report is intended as a solicitation to buy or sell any security. A third party, bedfordreport.com has paid Equity News Circuit four hundred and fifty dollars for the publication of this news release. Neither Equity News Circuit, nor the hiring party, has a financial relationship with any company whose stock is mentioned in this release.